Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.45 |
| ▸ | ACE | P12821 | 6/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.45 |
| ▸ | CPA1 | P15085 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25054045 | 0.77 | NPC1 (0.47) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL20881309 | 0.71 | CTSB (0.49) | — | |
| SCHEMBL3024846 | 0.70 | POLB (0.59) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL3024849 | 0.70 | POLB (0.59) | ALDH1A1MAPTHPGDMEN1KMT2A | |
| SCHEMBL13534695 | 0.69 | FFAR1 (0.55) | MMEACEACE2CPA1MMEL1 | |
| SCHEMBL19730726 | 0.68 | ALDH1A1 (0.50) | MMEACEACE2CPA1ALDH1A1 | |
| SCHEMBL159574 | 0.68 | TP53 (0.58) | MMEACEACE2CPA1ALDH1A1 | |
| SCHEMBL8283176 | 0.68 | TP53 (0.58) | MMEACEACE2CPA1ALDH1A1 | |
| SCHEMBL23261824 | 0.68 | FFAR1 (0.44) | ACEALDH1A1HPGDACACBMEN1 | |
| SCHEMBL16932220 | 0.68 | CAPN1 (0.52) | MMEACEACE2CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | MME 128/4885ACE 208/4885ACE2 12/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | MME 128/4885ACE 208/4885ACE2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.